Liquid Biopsy for Precision Oncology Summit West Coast leaderboard
  • Friday, November 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

SmartLab Exchange Europe 2027 Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Page 20

BioMarin to Acquire Alesta for Rare Bone Disease Drug

Aug 20, 2026
BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics in a deal aimed at adding a potential new treatment for hypophosphatasia (HPP), a rare genetic bone disease, to its…
Read More...

2nd T-Cell Engager for Autoimmune Disease Summit to Deliver 3 Days of Expert-Led Content to Advance…

Aug 19, 2026
Clinical translation insights to accelerate the development of differentiated autoimmune T-cell engager therapies. Following rapid progress in the autoimmune T-cell engager field,…
Read More...

Fulcrum and Slate Medicines Agree to $245 Million Merger

Aug 18, 2026
Fulcrum Therapeutics and Slate Medicines have agreed to combine in an all-stock merger that will create a company focused on developing new treatments for migraine and other headache…
Read More...

LEO Pharma Acquires Dersimelagon Rights for Rare Skin Diseases

Aug 18, 2026
LEO Pharma has agreed to acquire worldwide rights to dersimelagon from Tanabe Pharma in a deal that could reach up to $435 million in upfront and near-term milestone payments.…
Read More...

Sandoz and Henlius Expand Global Biosimilar Collaboration

Aug 17, 2026
Sandoz and Shanghai Henlius Biotech have entered into a major collaboration to develop, manufacture and commercialize biosimilar medicines, with the aim of expanding access to…
Read More...

FDA Grants Fast Track Status to Spevatamig for Biliary Cancer

Aug 17, 2026
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Phanes Therapeutics’ spevatamig for the treatment of patients with advanced and metastatic biliary…
Read More...

EMA Validates Pfizer and Valneva Lyme Disease Vaccine Application

Aug 17, 2026
The European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Pfizer and Valneva’s investigational Lyme disease vaccine, allowing the regulatory…
Read More...

FDA Approves Lantheus Tau PET Imaging Agent for Alzheimer’s

Aug 17, 2026
The U.S. Food and Drug Administration (FDA) has approved Lantheus Holdings’ TAUKLARIFY (florquinitau F 18 injection), a radiodiagnostic agent designed to help identify tau pathology in…
Read More...

Aurisco Passes FDA Inspection for Generic Oligonucleotide APIs

Aug 13, 2026
Aurisco Pharmaceutical has announced that its manufacturing site in Yangzhou, China, has successfully passed a U.S. Food and Drug Administration (FDA) inspection. The company said the…
Read More...

Alfasigma to Acquire Nordic Pharma in Global Expansion

Aug 13, 2026
Alfasigma S.p.A. has agreed to acquire Nordic Pharma, a specialty pharmaceutical company with operations across Europe, Canada and Japan, in a move that will expand Alfasigma’s…
Read More...
Previous 1 … 18 19 20 21 22 … 966 Next
Oligonucleotide-based Therapeutics Summit
LEAP HR: Life Sciences Europe
3rd Annual TRP Target Selection & Drug Design Summit
2nd Structure-Based Drug Design Summit San Diego
Liquid Biopsy for Precision Oncology Summit West Coast
2nd Non-Opioid Pain Therapeutics Summit
Muscular Disorders Drug Development Summit
Amylin-Based Therapeutics Summit
Cell Therapy for Autoimmune Disease Summit
Complement-Based Drug Development Summit
World CNS Summit South Korea
Novel CNS Biomarkers Summit Europe
8th CNS Drug Delivery Summit
Antigen-Specific Immune Tolerance Summit
7th Operationalize Expanded Access Programs Summit
Viral Vector Process Development & Manufacturing Summit
SmartLab Exchange Europe 2027
8th RNAi-Based Therapeutics Summit
17th World ADC London
PFS & Injectable Drug Devices Europe
Ophthalmic Drug Delivery Summit
Obesity & Weight Loss Drug Development Summit West
ADC Payload Summit 2026
10th Antifibrotic Drug Development Summit 2026
Biomarker Operations & Biospecimen Management
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • OBI Pharma Signs $2 Billion ADC Deal with Novartis
  • Erasca and Bristol Myers Squibb Partner on Pancreatic Cancer Treatment
  • GSK Wins FDA Approval for Nelkarmi in Advanced Lung Cancer
  • OXB Partners with Aura Biosciences for Phase 3 Cancer Drug Development
  • Skylark Bio Advances Hearing Loss Gene Therapy to Younger Children

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Cell Therapy Safety in Autoimmune Disease

7th Operationalize: Expanded Access Programs Summit East…

As AI and ICH M15 Transform Drug Development, Industry…

Industry Leaders Explore the Future of RNA Therapeutics…

Direct RNA Binding Emerges as a Powerful Approach for…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.